VIEW MENU
Pet Age
 

January 11, 2017

VetDC, Inc., a veterinary cancer therapeutics company, announced yesterday that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of Tanovea-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs. Tanovea-CA1 is anticipated to be available to veterinarians in the spring of 2017.

“This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” said Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”

“The conditional approval of Tanovea-CA1 represents a first on multiple levels for veterinary oncology, and we eagerly anticipate adding this very active and promising new drug to our lymphoma fighting arsenal,” noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at VCA-Katonah Bedford Veterinary Center in Bedford Hills, New York.

Share This Story On:

Enews Subscribe

Sign up for Pet Age's Weekly E-newsletter for the latest in pet business news, recalls and more.

Event Calendar

Events Calendar

« May 2017 » loading...
M T W T F S S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
close
Business Webinar Series
View recaps of our latest webinars here. Learn More